Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with Immunotherapy

Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with Immunotherapy

Due to the poor stability and adverse effects of chemotherapy drugs, such as gemcitabine, the current effectiveness of traditional chemotherapy is minimal. Some patients also show a low response rate to immunotherapy. Therefore, a novel material PD‐L1‐GEMs is designed and synthesized with targeted s...

Full description

Bibliographic Details
Main Authors: Xing Hu, Hongliang Zeng, Yongbo Peng, Minhua Deng, Wei Xiang, Biao Liu, Jiahao Liu, Yunlong Fu, Zhiqiang Hu, Weibin Hou, Xuewen Liu, Jin Tang, Zhi Long, Long Wang, Jianye Liu
Format: Article
Language:English
Published: Wiley-VCH 2023-12-01
Series:Small Science
Subjects:
bladder cancer
chemotherapy
immunotherapy
PD-L1 aptamers
targeted therapy
Online Access:https://doi.org/10.1002/smsc.202300104

Internet

https://doi.org/10.1002/smsc.202300104

Similar Items